CryoLife, Inc. — Form 10-Q Summary
Entity and period: The supplied filing identifies the registrant as CryoLife, Inc., not Artivion, Inc. It covers the unaudited quarter and six months ended June 30, 2012; comparisons are with the corresponding 2011 periods. Amounts below are in U.S. dollars unless noted.
Business context and results
CryoLife preserves cardiac and vascular tissues and sells medical devices, including BioGlue, PerClot, revascularization products, and—following its May 2012 acquisition of Hemosphere—the HeRO Graft. Management reported record quarterly revenue for a third consecutive quarter.
| Metric | Three months ended June 30, 2012 | Three months ended June 30, 2011 | Six months ended June 30, 2012 | Six months ended June 30, 2011 |
|---|---|---|---|---|
| Revenue | $33.2 million | $29.4 million | $65.5 million | $59.6 million |
| Gross margin | $21.4 million; 64.4% | $19.1 million; 64.8% | $42.7 million; 65.1% | $37.6 million; 63.0% |
| Operating income | $5.8 million | $3.8 million | $7.5 million | $6.2 million |
| Net income | $3.3 million | $1.8 million | $4.3 million | $3.5 million |
| Diluted EPS | $0.12 | $0.06 | $0.15 | $0.12 |
- Quarterly revenue grew 13%; six-month revenue grew 10%. Product revenue rose 15% for the quarter and 14% for the half year. Growth reflected higher BioGlue sales, the Cardiogenesis product line, and initial HeRO Graft sales; the prior-year comparison also included HemoStase revenue that had since ceased.
- For the quarter, preservation-services revenue increased 11%, and product revenue increased 15%. For the half year, preservation-services revenue increased 5% and product revenue increased 14%.
- Operating expenses were $15.5 million for the quarter and $35.2 million for the half year. Six-month general, administrative, and marketing expense rose 14% to $31.8 million, while research and development expense was $3.4 million, down slightly from 2011.
- Effective tax rates were approximately 41% for the quarter and 40% for the half year, compared with 52% and 45% in 2011.
Cash flow, balance sheet, and debt
- Six-month operating cash flow was $4.9 million, down from $7.9 million. Receivables and other working-capital movements were significant cash uses; receivables consumed $6.7 million, partly offset by a $3.9 million cash-flow benefit from payables and accrued liabilities.
- Investing activities used $19.3 million, including $17.1 million for the Hemosphere acquisition net of cash acquired. Financing activities used $3.3 million, primarily reflecting share repurchases.
- Cash and cash equivalents were $4.0 million at June 30, versus $21.7 million at December 31, 2011. An additional $5.0 million was restricted under the GE Capital credit agreement; $312,000 was also restricted for international tax obligations.
- Working capital was $50.4 million and the current ratio was 3:1, compared with $62.4 million and 4:1 at year-end 2011. Total liabilities were $32.4 million and shareholders’ equity was $124.2 million.
- No balance was drawn on the $20.0 million GE Capital revolving facility; $19.8 million remained available. The company reported covenant compliance. The facility expires October 28, 2014 and requires at least $5.0 million in restricted cash.
Material changes, unusual items, and outlook
- Hemosphere acquisition: Completed May 16 for a preliminary purchase price of approximately $22.0 million, funded with cash on hand. HeRO Graft contributed $635,000 of post-acquisition revenue in the quarter. The purchase-price allocation was preliminary and included $7.6 million of goodwill and $5.8 million of identifiable intangible assets. Up to $4.5 million of additional consideration is tied to revenue milestones through 2015; the acquisition-date fair value of the contingent liability was approximately $1.8 million.
- Litigation settlements: Medafor agreed to pay CryoLife $3.5 million and the settlement eliminated a $1.2 million payable; CryoLife recorded a $4.7 million gain, and received the first $1.75 million in July. CryoLife settled the CardioFocus case for $4.5 million, recording $4.1 million of expense in the first half and paying the settlement in July. These unusual items affected reported earnings and working capital.
- Management outlook: Management expected full-year 2012 preservation-services revenue to increase slightly from 2011. It expected higher full-year general, administrative, and marketing expenses due to expanded sales operations and Hemosphere, and higher research and development spending, including planned clinical studies. Management stated that existing cash and expected operating cash flow should cover operational liquidity needs for at least 12 months, while noting that acquisitions, clinical trials, and other activities could require additional financing.
- Product and market risks: BioGlue faced competitive pressure, domestic hospital budget constraints, and patent expiration outside the U.S. expected in mid-2013. Management cited potential foreign-exchange and European economic pressure on international sales. PerClot was not approved for U.S. sale; the company had refiled an investigational device exemption and was responding to FDA comments. Management estimated FDA approval in late 2014. Revascularization product sales faced competition and weak demand for capital equipment.
- Other exposures: The company disclosed tissue-processing and product-liability exposure, supplier and regulatory risks, acquired-business integration risks, and potential impairment of its Medafor and ValveXchange investments. A $2.4 million estimate for uncertain tax positions and related interest and penalties was excluded from the contractual-obligations schedule because payment timing could not be reliably estimated.
Investor verification priorities
- Confirm the issuer: the filing text is for CryoLife, Inc.; the request metadata names Artivion, Inc.
- Assess how much of earnings growth reflects ongoing operations versus the Medafor gain, CardioFocus expense, acquisition costs, and changes in effective tax rates.
- Track cash conversion and liquidity after the acquisition, July settlement payments, expected Medafor receipts, and the July $1.0 million advance to ValveXchange.
- Verify Hemosphere integration, HeRO Graft growth and reimbursement, contingent milestone exposure, and the final purchase-price allocation.
- Monitor FDA progress and timing for PerClot, competitive pressure on BioGlue and revascularization products, and the company’s stated revenue and expense outlook.